Βέλγιο - Ολλανδικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pharmathen s.a. - timololmaleaat 6,83 mg/ml - eq. timolol 5 mg/ml; latanoprost 50 µg/ml - oogdruppels, oplossing - 50 µg/ml - 5 mg/ml - latanoprost 50 µg/ml; timololmaleaat 6.83 mg/ml - timolol, combinations

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml); latanoprost, quantity: 0.05 mg/ml - eye drops, solution - excipient ingredients: sodium hydroxide; benzalkonium chloride; dibasic sodium phosphate; water for injections; sodium chloride; hydrochloric acid; monobasic sodium phosphate monohydrate - the reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins or other intraocular pressure lowering medications. latanocom should not be used to initiate therapy.

Βέλγιο - Γαλλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - chlorhydrate de dorzolamide 22,26 mg/ml - eq. dorzolamide 20 mg/ml; maléate de timolol 6,83 mg/ml - eq. timolol 5 mg/ml - collyre en solution - 20 mg/ml - 5 mg/ml - chlorhydrate de dorzolamide 22.26 mg/ml; maléate de timolol 6.83 mg/ml - timolol, combinations

Βέλγιο - Γαλλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

novartis pharma sa-nv - maléate de timolol 3,4 mg/ml - eq. timolol 2,5 mg/ml - collyre en solution - 0,25 % - maléate de timolol 3.4 mg/ml - timolol

Βέλγιο - Γαλλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

novartis pharma sa-nv - maléate de timolol 6,8 mg/ml - eq. timolol 5 mg/ml - collyre en solution - 0,5 % - maléate de timolol 6.8 mg/ml - timolol

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

akorn - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

sandoz inc - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see warnings ] ; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see warnings ] ; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. read this instructions for use that comes with timolol maleate ophthalmic solution before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your doctor about your medical condition or treatment. important information about timolol maleate ophthalmic solution: how should i use timolol maleate ophthalmic solution? the bottle is designed to assure the delivery of a precise dose of medication. before

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

bausch & lomb incorporated - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate sterile ophthalmic gel forming solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic gel forming solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see warnings, obstructive pulmonary disease ]; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see warnings, cardiac failure ]; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. timolol maleate ophthalmic gel forming solution 0.25% and 0.5% read this instructions for use that comes with timolol maleate ophthalmic gel forming solution before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your doctor about your medical condition or treatment. important information about timol

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

apotex corp - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution, usp 0.5% is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic solution  is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease (see warnings and precautions, 5.1, 5.3). timolol maleate ophthalmic solution  is contraindicated in patients with sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure (see warnings and precautions, 5.2 ); cardiogenic shock. timolol maleate ophthalmic solution  is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this product in the past. teratogenic effects: pregnancy category c: teratogenicity studies have been performed in animals. teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity. there are no adequate and well-controlled studies in pregnant women. timolol maleate ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. timolol has been detected in human milk following oral and ophthalmic drug administration. because of the potential for serious adverse reactions from timolol maleate ophthalmic solution in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. safety and effectiveness in pediatric patients have not been established. no overall differences in safety or effectiveness have been observed between elderly and younger patients.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

oceanside pharmaceuticals - timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - timolol maleate ophthalmic solution 0.5% is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. timolol maleate ophthalmic solution 0.5% is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [see warnings and precautions (5.1, 5.3)]. timolol maleate ophthalmic solution 0.5% is contraindicated in patients with sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock [see warnings and precautions (5.2)] . timolol maleate ophthalmic solution 0.5% is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this product in the past. teratogenic effects teratogenicity studies have been performed in animals. teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exp